|1.||Doi, H: 2 articles (10/2001 - 05/2000)|
|2.||Odawara, A: 1 article (10/2001)|
|3.||Karasawa, T: 1 article (10/2001)|
|4.||Katoh, M: 1 article (10/2001)|
|5.||Kaburaki, M: 1 article (05/2000)|
|6.||Narita, H: 1 article (05/2000)|
|7.||Suzumura, K: 1 article (05/2000)|
|8.||Inoue, H: 1 article (05/2000)|
03/01/1998 - "These results indicate that TA-993 has an antithrombotic effect on femoral arterial thrombosis and suggest that an increasing action on femoral blood flow of TA-993 is more relevant than its antiplatelet action to the antithrombotic effect in this model."
03/01/1998 - "We evaluated the antithrombotic effect of TA-993 in a canine model of femoral arterial thrombosis. "
03/01/1998 - "Antithrombotic action of TA-993, a new 1,5-benzothiazepine derivative, in a canine model of femoral arterial thrombosis."
04/01/1996 - "Orally administered TA-993 dose-dependently inhibited ADP-induced platelet aggregation ex vivo in dogs (0.3 to 10 mg/kg), significantly protected mice against collagen + epinephrine-induced thromboembolic death (10 mg/kg), and inhibited thrombus formation in an arteriovenous shunt in rats (30 mg/kg). "
|3.||Adenosine Diphosphate (ADP)